drugset
drugset / Trial / NCT01587144

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

NCT01587144 ↗

Phase 2 Terminated 18 enrolled Spectrum Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine the effectiveness of an investigational drug called lucanthone, when combined with temozolomide (TMZ) and radiation in the treatment of Glioblastoma Multiforme (GBM).

Timeline

Start
2012-06-19
Primary completion
2013-04-15
Completion
2013-04-15

Outcome

Outcome not reported

Stopped: “Sponsor's decision”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lucanthone Small molecule 10 mg/kg Oral
Comparator Lucanthone Small molecule 15 mg/kg Oral
Comparator Temozolomide Small molecule 150 mg/m2 —
Comparator Temozolomide Small molecule 200 mg/m2 —

Indications

glioblastoma